CD276

Across TCGA pan-cancer cohorts, CD276 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CD276 data layer compared with 30 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD276 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD276 expression acts as an unfavorable survival marker.

PDAC, LSCC, and CCRCC are the cancer types where CD276 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.291	0.562	<.001	74	view →
LSCC	OS	Median	All	0.723	0.908	.001	33	view →
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	25	view →
HNSC	OS	Median	IV	0.567	0.879	<.001	20	view →
LUAD	OS	Quartile	III,IV	0.204	0.758	.011	11	view →
GBM	DFS	Median	All	0.261	0.463	.003	10	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CD276–PDAC (DFS)

Open the PDAC breakdown →